Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Muscle Strain

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    51 result(s) found for: Muscle Strain. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2020-005165-14 Sponsor Protocol Number: TK-254R-0201 Start Date*: 2021-03-25
    Sponsor Name:Teikoku Seiyaku Co Ltd.
    Full Title: Randomized, controlled, double-blind, multi-center trial to evaluate the
    Medical condition: Acute strains, sprains or bruises of the extremities following blunt trauma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004863 10002549 Ankle sprain LLT
    20.0 100000004863 10002550 Ankle sprains and strains LLT
    20.0 100000004863 10028338 Muscle sprains LLT
    20.0 100000004859 10028361 Muscular pain LLT
    21.1 100000004859 10028362 Muscular pains LLT
    20.1 100000004863 10006502 Bruise LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-004215-35 Sponsor Protocol Number: TENPET Start Date*: 2005-01-19
    Sponsor Name:Turku PET Centre
    Full Title: Influence of muscle specific activation on regional glucose uptake in the human Achilles tendon
    Medical condition: The combined forces generated by the triceps surae muscles causes non-uniform strain within the human triceps aponeuroses. This may cause non-uniform tendon force that would result in intratendinou...
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: FI (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-002520-33 Sponsor Protocol Number: SNT-II-1 Start Date*: 2005-09-06
    Sponsor Name:Santhera Pharmaceuticals LLC
    Full Title: A Phase IIa double blind, randomised, placebo controlled, single centre study at the university of Leuven to assess the efficacy and tolerability of idebenone in 10 - 16 year old males with cardiac...
    Medical condition: Duchenne Muscular Dystrophy
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2016-004825-17 Sponsor Protocol Number: preTopic17 Start Date*: 2017-12-06
    Sponsor Name:Charité Universitätsmedizin Berlin
    Full Title: A Proof-of-concept study to investigate the Efficacy of Telbivudine Over Placebo in patients with Parvovirus-associated Inflammatory Cardiomyopathy
    Medical condition: Parvovirus B19-induced inflammatory cardiomyopathy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2024-000001-33 Sponsor Protocol Number: C4591048 Start Date*: 2024-02-07
    Sponsor Name:BioNTech SE
    Full Title: A Master Phase 1/2/3 Protocol to Investigate the Safety, Tolerability, and Immunogenicity of Variant-Adapted BNT162b2 RNA-Based Vaccine Candidate(s) in Healthy Children
    Medical condition: Protection against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2)
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    23.0 10021881 - Infections and infestations 10084510 Coronavirus infections HLT
    23.1 10021881 - Infections and infestations 10084529 2019 novel coronavirus infection LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-004313-13 Sponsor Protocol Number: C3511001 Start Date*: 2020-08-27
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 3, RANDOMIZED, ACTIVE-CONTROLLED, OBSERVER-BLINDED TRIAL TO ASSESS THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MenABCWY IN HEALTHY PARTICIPANTS ≥10 TO <26 YEARS OF AGE
    Medical condition: Invasive Meningococcal Disease (IMD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10076061 Meningococcal immunisation PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DK (Completed) CZ (Completed) HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-002213-60 Sponsor Protocol Number: GX1001 Start Date*: 2019-01-08
    Sponsor Name:Solid Biosciences Inc.
    Full Title: A randomized, controlled, open-label, single-ascending dose, phase I/II study to investigate the safety and tolerability, and efficacy of intravenous SGT-001 in male adolescents and children with D...
    Medical condition: Duchenne muscular dystrophy
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10052655 Duchenne muscular dystrophy gene carrier PT
    20.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2020-002641-42 Sponsor Protocol Number: C4591001 Start Date*: 2020-09-04
    Sponsor Name:BioNTech SE
    Full Title: A PHASE 1/2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COV...
    Medical condition: Protection against COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-000150-22 Sponsor Protocol Number: T14/2018 Start Date*: 2018-06-05
    Sponsor Name:Turku University Hospital
    Full Title: Intravesical instillation therapy with bacillus Calmette-Guérin (BCG) and sequential BCG and electromotive Mitomycin-C (EMDA-MCC) in patients with high risk non-muscle-invasive bladder carcinoma
    Medical condition: Non-muscle invasive bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-000607-41 Sponsor Protocol Number: MMC-BCG-1 Start Date*: 2011-03-04
    Sponsor Name:Centre Hospitalier de Jolimont-Lobbes-Tubize-Nivelles
    Full Title: A phase I/II multicentric Belgian prospective novel sequential chemo-immunotherapy regimen for adjuvant treatment in non-muscle invasive bladder cancer.
    Medical condition: Patients with intermediate/high risk non-muscle invasive bladder cancer (NMIBC) • intermediate risk tumours – Ta, T1 Grade 1, Grade 2, multifocal and tumours larger than 3 cm • high risk tumours – ...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-005903-11 Sponsor Protocol Number: C4591017 Start Date*: 2022-01-20
    Sponsor Name:BioNTech SE
    Full Title: A Phase 3, Randomized, Observer-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of The Vaccine Candidate BNT162b2 Against COVID-19 i...
    Medical condition: SARS-CoV-2 Infection
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-004149-26 Sponsor Protocol Number: METRIS-HF(EMPA) Start Date*: 2018-06-26
    Sponsor Name:Charité Universitätsmedizin Berlin
    Full Title: Effect of Metformin and Empagliflozin in insulin resistant patients with heart failure with reduced ejection fraction
    Medical condition: Heart Failure with reduced ejection fraction (HFrEF and HFmrEF)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003822-42 Sponsor Protocol Number: B1971048 Start Date*: 2015-01-30
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A Phase 4, Single-Arm, Open-Label Study describing the safety and immunogenicity of Bexsero in healthy subjects aged 12 years to <19 years.
    Medical condition: Test the safety and immunogenicity of Bexsero used as a vaccine for Neisseria meningitidis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10021881 - Infections and infestations 10027249 Meningitis meningococcal PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-002242-17 Sponsor Protocol Number: B00844 Start Date*: 2020-07-30
    Sponsor Name:Manchester University NHS Foundation Trust
    Full Title: A randomised, double-blind, placebo-controlled, phase 2 evaluation of the efficacy and mechanism of trientine in patients with hypertrophic cardiomyopathy.
    Medical condition: Hypertrophic Cardiomyopathy (HCM)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10020871 Hypertrophic cardiomyopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2021-003458-22 Sponsor Protocol Number: BNT162-17 Start Date*: 2021-10-04
    Sponsor Name:BioNTech SE
    Full Title: A Phase II trial to evaluate the safety and immunogenicity of SARS-CoV-2 monovalent and multivalent RNA-based vaccines in healthy subjects
    Medical condition: Protection against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2).
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    23.0 10021881 - Infections and infestations 10084510 Coronavirus infections HLT
    23.1 10021881 - Infections and infestations 10084529 2019 novel coronavirus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020489-82 Sponsor Protocol Number: Q16-10-01 Start Date*: 2010-08-25
    Sponsor Name:Fidia Farmaceutici S.p.A.
    Full Title: Randomised, double-blind, placebo-controlled, parallel-groups, multi-centre clinical trial Phase III with Diclofenac Sodium 140 mg medicated plaster in patients with fresh impact injuries of the li...
    Medical condition: Fresh impact injuries of the limbs (Contusions, strains and sprains)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000222-35 Sponsor Protocol Number: 2017-000222-35 Start Date*: 2017-07-21
    Sponsor Name:Medical University of Vienna
    Full Title: Effect of etelcalcetide on cardiac hypertrophy in hemodialysis patients – a randomized controlled trial
    Medical condition: Secondary hyperparathyroidism in adult patients with chronic kidney disease on hemodialysis therapy.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003581-27 Sponsor Protocol Number: CA209-9UT Start Date*: 2020-07-03
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 2, Randomized, Open-label Study of Nivolumab or Nivolumab/BMS-986205 Alone or Combined with Intravesical BCG in Participants with BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Ca...
    Medical condition: BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005005 Bladder cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) ES (Prematurely Ended) GB (GB - no longer in EU/EEA) NL (Completed) IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2018-002571-18 Sponsor Protocol Number: 170KG18 Start Date*: 2019-07-22
    Sponsor Name:University Medical Center Groningen
    Full Title: EFFECT OF FERRIC CARBOXYMALTOSE ON EXERCISE CAPACITY AFTER KIDNEY TRANSPLANTATION: A MULTICENTER RANDOMIZED CONTROLLED TRIAL
    Medical condition: Iron deficiency in kidney transplant recipients
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10022971 Iron deficiencies HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000698-26 Sponsor Protocol Number: FGCL-3019-093 Start Date*: 2023-01-17
    Sponsor Name:FibroGen, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination with Systemic Corticosteroids in Subjects with Non-ambulatory Duchenne Muscular Dystrophy (DMD)
    Medical condition: Non-ambulatory Duchenne Muscular Dystrophy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male
    Trial protocol: FR (Prematurely Ended) AT (Prematurely Ended) CZ (Prematurely Ended) NL (Prematurely Ended) BE (Prematurely Ended) GB (GB - no longer in EU/EEA) IT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 21:11:46 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA